Literature DB >> 2224859

Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.

C S Murphy1, J J Pink, V C Jordan.   

Abstract

We have established an estrogen receptor- and progesterone receptor-negative, hormone-nonresponsive breast cancer cell line from a receptor-positive, hormone-responsive line grown under estrogen-free conditions. T47D breast cancer cells were cultured under estrogenized conditions (in phenol red-containing medium supplemented with whole fetal bovine serum) and cloned to produce line T47D:A18. The parental T47D line was also estrogen deprived (in phenol red-free medium supplemented with dextran-coated charcoal-treated fetal bovine serum) for more than 1 year and subsequently clone T47D:C4 was established. T47D:A18 was estrogen receptor and progesterone receptor positive as determined by both ligand binding assay analysis and enzyme immunoassay analysis. T47D:C4 cells were estrogen receptor and progesterone receptor negative and mRNA for these receptors was not detected. Incubation of hormone-responsive T47D:A18 cells with 17 beta-estradiol caused a 3-fold increase in cell growth over 8 days when compared to control. This stimulation of growth was completely inhibited by the anti-estrogens 4-hydroxytamoxifen (0.1 microM) and ICI 164,384 (1.0 microM). Receptor-negative T47D:C4 cells were refractory to the effects of both 17 beta-estradiol and the antiestrogens. T47D:A18 cells grown under both estrogen-containing and estrogen-free conditions expressed low levels of transforming growth factor (TGF)-alpha and epidermal growth factor receptor mRNA. In the presence of estrogen, high levels of TGF-beta 1 mRNA were detected in T47D:A18 cells. These levels decreased when T47D:A18 cells were grown in estrogen-free media. Conversely, TGF-beta 2 mRNA was not detected in T47D:A18 cells cultured under estrogenic conditions; however, message was detected after the cells were cultured under estrogen-free conditions. T47D:C4 cells expressed low levels of TGF-alpha, epidermal growth factor receptor, TGF-beta 1, and TGF-beta 2 mRNA. These studies characterize a novel hormone-nonresponsive cell line which has been established from a hormone-responsive cell line grown under estrogen-free and drug-free conditions. Further analysis of these lines should provide valuable information concerning the development of antiestrogen-resistant breast cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2224859

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.

Authors:  Surojeet Sengupta; Michael C Biarnes; Robert Clarke; V Craig Jordan
Journal:  Breast Cancer Res Treat       Date:  2015-02-27       Impact factor: 4.872

2.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

3.  Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.

Authors:  Sujoy Dutta; Chirosree Bandyopadhyay; Virginie Bottero; Mohanan V Veettil; Lydia Wilson; Michael R Pins; Karen E Johnson; Case Warshall; Bala Chandran
Journal:  Mol Oncol       Date:  2014-01-04       Impact factor: 6.603

4.  The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

Authors:  Joan S Lewis-Wambi; Helen Kim; Ramona Curpan; Ronald Grigg; Mohammed A Sarker; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2011-07-07       Impact factor: 4.436

5.  A polymerase chain reaction-based microsatellite typing assay used for tumor cell line identification.

Authors:  B L King; A Lichtenstein; J Berenson; B M Kacinski
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

Review 6.  The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.

Authors:  V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2014-10-22       Impact factor: 5.678

7.  Interaction Between MUC1 and STAT1 Drives IFITM1 Overexpression in Aromatase Inhibitor-Resistant Breast Cancer Cells and Mediates Estrogen-Induced Apoptosis.

Authors:  Taylor E Escher; Asona J Lui; Eric S Geanes; Katherine R Walter; Ossama Tawfik; Christy R Hagan; Joan Lewis-Wambi
Journal:  Mol Cancer Res       Date:  2019-01-17       Impact factor: 5.852

8.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 9.  William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Effects of tamoxifen on human breast cancer cells in vitro.

Authors:  W E Simon; G Trams; F Hölzel
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.